Labcorp Inc.

LH | NYSE

Price Alert Chart Builder DCF Calculator

$311.54

-$9.45 (-2.94%)

At close: Sep 22, 2026, 4:00 PM ET

$311.54

$0 (0.00%)

After-hours: Sep 22, 2026, 5:38 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

-2.94%

(1D)

Rating

Updated: Sep 12, 2026

38.7

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $25.55B

1D Range

303.46 316.53

52W Range

244.52 341.80

Valuation (TTM)

PE 26.55

PB 3.06

EV/EBITDA 15.31

Valuation (NTM)

Forward PE 16.00

Forward PEG 3.12

Price Target $340.75

Cash Flow

FCF Yield 4.4%

SBC Adj. FCF Yield 3.9%

SBC Impact -10.9%

Margins

Gross Margin 27.9%

Operating Margin 11.3%

FCF Margin 8.1%

Growth (CAGR)

Revenue 3Y | 5Y 4.4% | -2.6%

Dil EPS 3Y | 5Y 9.3% | -16.2%

FCF 3Y | 5Y 2.5% | -16.4%

Returns

ROA 5.4%

ROE 11.6%

ROIC 7.9%

Financial Health

Net Debt

$5.72B

Current Ratio 1.80

Interest Coverage 7.12

Dividends

Div Yield 0.90%

Payout Ratio 23.8%

FCF Payout Ratio 20.7%

All Key Statistics

Loading financial charts...

Profile

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-inf...

Sector Healthcare

Industry Medical - Diagnostics & Research

Employees 71,000

IPO Date Mar 28, 1990

Website www.labcorp.com

Fiscal Year January - December

Full Company Profile

Latest News

1 day ago · seekingalpha.com

Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts

Labcorp Holdings Inc. is upgraded to Buy, supported by resilient demand for diagnostics and robust Q2 results, despite upcoming Medicare rate cuts. LH outperformed both the S&P 500 and healthcare peers YTD, with strong technical support and positive operating margins. Revenue durability, new test launches, and a diversified biopharma segment bolster LH's growth and risk profile amid regulatory headwinds.

1 day ago · fool.com

Why Labcorp Holdings Stock Dropped Today

Medicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.

9 days ago · seekingalpha.com

Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

13 days ago · seekingalpha.com

Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript

14 days ago · benzinga.com

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.

14 days ago · prnewswire.com

Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day

Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment BURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m.